Last update April 15, 2024

Olmesartan Medoxomil

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once a day.

At latest update, relevant published data on excretion into breast milk were not found.

Its high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.

An infant whose mother was taking olmesartan (dose not reported) presented with weight loss and increased liver transaminases in the third week of life that resolved after stopping the medicationSalimova 2023)

Safer alternative drugs are preferred (Malachias 2016, Rowe 2013), especially in premature babies or during the neonatal period.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Olmesartan Medoxomil in other languages or writings:

Tradenames

Main tradenames from several countries containing Olmesartan Medoxomil in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 4.5 - 28.6 %
Molecular weight 559 daltons
Protein Binding 99 %
VD 0.2 - 0.4 l/Kg
pKa 0.89 -
Tmax 1 - 3 hours
10 - 15 hours

References

  1. Salimova M, Maggi M, Crevani M, Maida F, Bissoli M, Ferruzzi M, Scaglione F. Olmesartan-induced reversible transaminase elevation in a breastfed newborn. A case report. Neurotoxicol Teratol 2023;98:24 Abstract
  2. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  3. AEMPS. Olmesartán. Ficha técnica. 2014 Full text (in our servers)
  4. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  5. Merck. Olmesartan. Drug Summary. 2013 Full text (in our servers)
  6. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)

Total visits

14,408

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM